Reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sampling and sample preparation influence measured purity. Peptides are often hygroscopic, so weighing should occur quickly under controlled humidity to avoid water uptake. Complete dissolution in a suitable solvent is necessary before injection; undissolved material can block columns or distort results. Filtration removes particulates but may also remove aggregates if the filter pore size is too small. Impurities can originate from synthesis, cleavage, purification, or storage, and forced degradation under heat, light, oxidation, or pH extremes can help identify degradation pathways.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
| Property | Value | Notes |
|---|---|---|
| Quality specification | Lot-specific; often 95% or greater by HPLC area | Thresholds depend on intended use and analytical method. |
| Documentation | Certificate of analysis | Includes method details, results, and storage guidance. |
| Sample preparation | Dissolve in suitable solvent; filter if needed | Avoid contamination and ensure complete dissolution. |
| Method validation | Accuracy, precision, specificity, linearity | Required for regulated or accredited testing. |
| Common impurity classes | Deletion, oxidation, deamidation, truncation | Identified by chromatography and mass spectrometry. |
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Purity results are only meaningful when linked to a defined sample and method. A certificate of analysis typically lists the analytical technique, column type, gradient, detection wavelength, and integration parameters. It may also report mass confirmation, water content, and counterion composition. For research peptides, laboratories often request the raw chromatogram rather than only a summary percentage. This allows independent review of baseline, peak shape, and any unresolved shoulders that might be missed by a single number.
Stability testing examines how purity changes under controlled conditions. Samples are stored at defined temperatures, such as -20 °C or -80 °C, and analyzed at intervals. Lyophilized powders are generally more stable than solutions because water promotes hydrolysis and aggregation. Repeated freeze-thaw cycles can also degrade peptides, especially those with oxidation-prone residues. Accelerated studies at elevated temperature provide useful comparisons, but they do not always predict long-term behavior at lower temperatures.
Handling practices strongly affect measured purity and sample integrity. Many peptides are hygroscopic, susceptible to oxidation, or prone to adsorption on glass and plastic surfaces. Lyophilized powders are typically stored desiccated at -20 °C or below, while solutions may require colder storage and minimized freeze-thaw cycles. Peptides containing cysteine, methionine, or tryptophan can degrade through oxidation or disulfide exchange. Working aliquots reduce repeated exposure to moisture and temperature fluctuations during routine analysis.
Purity values do not necessarily predict biological potency. Net peptide content corrects for counterions such as acetate or trifluoroacetate, water, and residual salts. Impurity thresholds for reporting, identification, and qualification are often set according to regulatory guidance, though specific limits depend on the product class and route of administration. Open questions remain about the toxicological relevance of low-level peptide impurities and about how best to compare results across different analytical platforms. A certificate of analysis should state the methods used and the basis for each reported value.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
=== 90Sr === Strontium-90 has been used by the Soviet Union in terrestrial RTGs. 90Sr decays by β− decay into 90Y, which quickly β-decays again. It has a lower decay energy than 238Pu, but its shorter half-life of 28.8 years and lower atomic weight yield a power density for pure metal of 0.95 watts per gram. As 90Sr is a very reactive alkaline earth metal and a bone seeker that accumulates in bone-tissue due to its chemical similarity to calcium (once in the bones it can significantly damage the bone marrow, a rapidly dividing tissue), it is usually not used in pure form in RTGs. The most common form is the perovskite strontium titanate (SrTiO3) which is chemically nigh-inert and has a high melting point. While its Mohs hardness of 5.5 has made it ill-suited as a diamond simulant, it is of sufficient hardness to withstand some forms of accidental release from its shielding without too fine dispersal of dust. The downside to using SrTiO3 instead of the native metal is it reduces power density, as the TiO3 part of the material does not produce any decay heat. 90Sr has a high fission product yield in the fission of both 235U and 239Pu and is thus available in large quantities at a relatively low price if extracted from spent nuclear fuel. Starting from the oxide or the native metal, one pathway to obtaining SrTiO3 is to let it transform to strontium hydroxide in aqueous solution, which absorbs carbon dioxide from air to become less soluble strontium carbonate.
The beef hormone controversy or beef hormone dispute is a disagreement over the use of growth hormones in beef production. In 1989, the European Communities banned the import of meat that contained artificial beef growth hormones, although they were approved for use in the United States. In 2003 estradiol-17β was permanently banned, while provisionally banning five others. World Trade Organization (WTO) rules permit such bans, but only where a signatory presents valid scientific evidence that the ban is a health and safety measure. Canada and the United States opposed this ban, taking the EU to the WTO Dispute Settlement Body. In 1997, the WTO Dispute Settlement Body ruled against the EU. It remains one of the most intractable agricultural trade controversies since the establishment of the WTO. It is not the same as the UK–EU dispute over bovine spongiform encephalopathy, although both have been termed the "beef war".
In order to maintain the cell membrane potential, cells keep a low concentration of sodium ions and high levels of potassium ions within the cell (intracellular). The sodium–potassium pump mechanism moves 3 sodium ions out and moves 2 potassium ions in, thus, in total, removing one positive charge carrier from the intracellular space (see § Mechanism for details). In addition, there is a short-circuit channel (i.e. a highly K-permeable ion channel) for potassium in the membrane, thus the voltage across the plasma membrane is close to the Nernst potential of potassium.
Sources: en.wikipedia.org
== Diagnosis == Weissenbacher-Zweymüller syndrome is diagnosed upon a thorough clinical evaluation, detailed patient history, identification of characteristic symptom and a variety of specialized tests which includes x-rays.
MPEG LA is making claims that DisplayPort implementation requires a license and a royalty payment. It is important to note that these are only CLAIMS. Whether these CLAIMS are relevant will likely be decided in a US court. By March 2017, that statement had been removed from the official FAQ, while the various other references to being royalty-free were kept. By November 2018, mentions of DisplayPort being royalty-free were removed from the FAQ. While VESA does not charge any per-device royalty fees, VESA requires membership for access to said standards. The minimum cost is presently $5,000 (or $10,000 depending on Annual Corporate Sales Revenue) annually.
== Selected articles == Meyer, D. E., & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nature Biotechnology, 17(11), 1112–1115. Nath, N., & Chilkoti, A. (2002). A colorimetric gold nanoparticle sensor to interrogate biomolecular interactions in real time on a surface. Analytical chemistry, 74(3), 504–509. Ma, H., Hyun, J. Chilkoti, A. (2004). "Nonfouling" oligoethylene glycol functionalized polymer brushes synthesized by surface-initiated atom transfer radical polymerization. Advanced Materials, 16, 338–341. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 98(5), 335–344. Ciracì, C., Hill, R. T., Mock, J. J., Urzhumov, Y., Fernández-Domínguez, A. I., Maier, S. A., ... & Smith, D. R. (2012). Probing the ultimate limits of plasmonic enhancement. Science, 337(6098), 1072–1074.
Sources: en.wikipedia.org
A certificate of analysis reports test results, methods, and specifications for a peptide lot. It often includes appearance, purity by chromatography, mass confirmation, and storage recommendations. It supports quality assessment but does not by itself guarantee suitability for every application.
Impurities are separated by chromatography and then characterized by mass spectrometry, sometimes with tandem mass spectrometry or sequencing. Common impurities include deletion peptides, oxidized forms, deamidated forms, and residual solvents. Identification can be challenging when impurities co-elute or are present at very low levels.
Storage conditions can change measured purity because degradation increases impurity peaks over time. Temperature, moisture, light exposure, and repeated freeze-thaw cycles are common influences. Re-testing after storage may therefore produce different results from the original certificate of analysis.
It measures the relative ultraviolet absorbance area of peptide peaks, usually at 214 nm. It does not directly measure mass, water, counterions, or co-eluting species.